Reading this on a mobile device? Try our optimized mobile version here:

December 28, 2012News for medical technology professionals

  Top Story 
  • Oculus secures U.S. patent for skin ulcer technology
    Oculus Innovative Sciences has received a U.S. patent for its Microcyn Technology to be used in treating patients with skin ulcers. The technology is administered to skin ulcers either by irrigation, soaking and washing, or by applying a wound dressing that has been soaked with the technology. (12/27) LinkedInFacebookTwitterEmail this Story
  Business & Market Trends 
  • Funding round brings in $12M for GoBalto
    A Series B financing round headed by the Economic Development Board Investments in Singapore has pulled in $12 million for GoBalto. The San Francisco startup is focused on providing cloud-based solutions to aid medical device, drug and biotechnology firms in conducting clinical studies. (12/27) LinkedInFacebookTwitterEmail this Story
  International Developments 
  Science & Health 
  • Svelte Medical begins heart stent trial in Europe
    Svelte Medical Systems said its Svelte Acrobat Integrated Delivery System has been implanted in the first patient participating in a study to compare the technology with traditional coronary stent devices in treating lesions in patients whose conditions make them able to receive direct stenting. The trial will involve as many as 300 patients from 12 clinical sites in Spain, Belgium and France. (Boston) (12/26) LinkedInFacebookTwitterEmail this Story
  • MRI can identify Alzheimer's disease noninvasively
    The brain scans of 185 patients who had been diagnosed through lumbar punctures as having either Alzheimer's disease or frontotemporal lobar degeneration were analyzed by University of Pennsylvania researchers who found that the MRI scans can distinguish between the two forms of dementia with a similar accuracy rate to the lumbar puncture. The study, published in the journal Neurology, found that structural brain patterns that show up on MRI scans can help doctors make the correct diagnosis about 75% of the time, making the MRI a useful tool in differentiating between the two forms of dementia, which have similar symptoms. (12/27) LinkedInFacebookTwitterEmail this Story
  Emerging Technologies 
  • Micromedic's device shows promise in cervical cancer Dx study
    Micromedic Technologies said its CellDetect system for diagnosing cervical cancer showed positive results in a clinical study. The trial examined 42 samples of urine using technology from Zetiq, a portfolio company of Micromedic, and compared the results with either cystoscopies or biopsies. Globes (Israel) (12/25) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
AdvaMed News 
  • Investigational Device Exemption (IDE) Submissions Workshop
    Wednesday, Feb. 27
    Sheraton Crystal City, Arlington, Va.
    MTLI offers this one-day interactive workshop to lead attendees through the regulatory and practical guidelines governing when an IDE is required, how to compile an effective IDE application, the rules governing clinical studies and human subject protection, Institutional Review Boards, types of pre-IDE meetings and communications, early/expanded access, foreign studies and export, and reimbursement for investigational devices. Visit MTLI online for more information. LinkedInFacebookTwitterEmail this Story
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

Position TitleCompany NameLocation
IP Litigation Counsel III - 001980Edwards LifesciencesIrvine, CA
Senior Director, Clinical Programs - Transcatheter Heart ValveEdwards LifesciencesIrvine, CA
Clinical DirectorStrykerFreemont, CA
Clinical Project ManagerEndologix, Inc.Irvine, CA
Physician Training Program ManagerEndologix, Inc.Irvine, CA
Strategic Sourcing Manager Alpha Source, Inc.Milwaukee, WI
Click here to view more job listings.

  Editor's Note 
  • Correction
    A headline in a news item on Thursday incorrectly stated the number of nations that signed a statement of cooperation to develop the Medical Device Single Audit Program. Regulators for the U.S. and three other nations signed the statement. SmartBrief regrets the error. LinkedInFacebookTwitterEmail this Story
If all misfortunes were laid in one common heap whence everyone must take an equal portion, most people would be contented to take their own and depart."
Greek philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
A powerful website for SmartBrief readers including:
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information